Artificial Intelligence in Genomics: Driving Innovation in Healthcare and Beyond

The Artificial Intelligence in Genomics Market is expected to reach $6.22 billion by 2029, at a CAGR of 42.8% from 2022 to 2029.

Introduction to Artificial Intelligence in Genomics Market

Genomics involves the study of genomes through the analysis, sequencing, and mapping of genes. With the integration of artificial intelligence (AI), genomics is experiencing a significant transformation. AI has found applications in various aspects of genomics, such as variant calling, genome annotation, variant classification, and genetic diagnosis. The rapid advancements in technology are improving the accuracy, reducing the cost, and shortening the time required to map the human genome. As a result, many companies are heavily investing in genomics to unlock its potential in drug discovery, diagnostics, and precision medicine.

Download Sample Copy Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5345 

Genomic Research Applications

The growing knowledge and understanding of genomic research have found applications across multiple fields, including medicine, biotechnology, agriculture, and even social sciences. In recent years, the application of AI in genomics has soared, leading to an increased ability to process and analyze complex genetic data. According to the National Human Genome Research Institute, genomic research is expected to generate an enormous amount of data—between 2 and 40 exabytes—within the next decade. This increase in data complexity, driven by DNA sequencing and other biological techniques, requires advanced computational tools. AI-based platforms are proving indispensable in helping genomic researchers manage, extract, and analyze these massive datasets.

AI’s Role in Genomic Data Interpretation

AI tools are playing a pivotal role in enhancing the interpretability of genomic data. They can convert raw genomic data into actionable clinical insights, which can be applied in the development of targeted therapies for specific patient groups. AI is making it easier for researchers to identify novel drug targets, understand genetic mutations, and develop precise treatments based on individual genetic profiles. This shift is paving the way for more personalized medicine, where AI contributes directly to improving patient outcomes by offering targeted and effective therapies.

Investments in AI-Driven Genomics Platforms

With the growing influence of AI in genomics, several AI platform developers are actively seeking funding to advance their technologies further. For instance, Illumina Accelerator, a funding support program developed by Illumina, Inc., invested in seven omics startups in March 2022. This initiative aimed to support breakthrough developments in therapeutics, diagnostics, DNA storage, and mental wellness. One of the startups, NonExomics, Inc., is utilizing AI to develop a proprietary platform that maps novel drug targets from previously uncharacterized regions of the genome.

In another example, DNAnexus, a developer of cloud-based biomedical data analysis software, secured $200 million in financing to enhance its genomics and multi-omics platform using AI and machine learning (ML) tools. Similarly, SeqOne Genomics, a cloud-based biotech company based in France, raised $23.66 million to develop genomic analysis solutions for personalized medicine with AI-driven platforms.

Notable Funding in the AI and Genomics Space

The AI genomics space has also attracted significant attention from investors. In July 2021, Deep Genomics, a Canadian AI therapeutics company, raised $180 million in a series C funding round. This funding round was led by prominent investors such as Fidelity Management & Research Company, the Canadian Pension Plan Investment Board (CPP Investments), and Alexandria Venture Investments. These funds are directed toward enhancing AI platforms that target genetic mutations, thereby contributing to the development of breakthrough therapeutic solutions.

Public and Private Funding in AI-Driven Genomics Research

In addition to private investments, public organizations are also stepping in to support AI-driven genomics research. For example, the National Human Genome Research Institute in the U.S. is providing funding for AI and ML-driven genomics research aimed at solving complex biomedical challenges. These public investments are helping tackle significant issues related to precision medicine, allowing researchers to address disease on a genetic level and develop targeted therapies that have the potential to revolutionize healthcare.

Conclusion

The integration of artificial intelligence in genomics is transforming the way genetic research is conducted, leading to groundbreaking advancements in the field. With AI’s ability to analyze complex genomic data efficiently, companies and researchers are leveraging this technology to develop new diagnostic tools, enhance drug discovery processes, and offer precision medicine solutions. As funding for AI-driven genomics continues to grow, both from private investors and public organizations, the global AI in genomics market is expected to witness exponential growth, projected to reach $6.22 billion by 2029 at a remarkable CAGR of 42.8%. This growing partnership between AI and genomics is poised to bring transformative changes across various sectors, especially healthcare, as it continues to unlock the potential of personalized medicine.

Key Players

The key players operating in the global AI in genomics market are Microsoft Corporation (U.S.), NVIDIA Corporation (U.S.), Deep Genomics Incorporated (Canada), Fabric Genomics, Inc. (U.S.), Data4Cure, Inc. (U.S.), Predictive Oncology Inc. (U.S.), Emedgene Technologies LTD (U.S.), Congenica Ltd. (U.K.), Tempus Labs, Inc. (U.S.), SOPHiA GENETICS SA (Switzerland), Illumina Inc. (U.S.), and BenevolentAI Limited. (U.K.).

Purchase Now : https://www.meticulousresearch.com/Checkout/40485578

Scope of the Report:

Artificial Intelligence in Genomics Market, by Offering

• Software
• Services

Artificial Intelligence in Genomics Market, by Delivery Mode

• On-premises
• Cloud & Web-Based Mode

Artificial Intelligence in Genomics Market, by Functionality

• Genome Sequencing
• Gene Editing
• Other Functionalities
  (Note: Other functionalities include pharmacogenomics and predictive gene testing.)

Artificial Intelligence in Genomics Market, by Application

• Drug Discovery & Development
• Precision Medicine
• Diagnostics
• Other Applications
  (Note: Other applications include agriculture, pharmacology, and animal health.)

Artificial Intelligence in Genomics Market, by End User

• Pharmaceutical & Biopharmaceutical Companies
• Academic & Research Institutes
• Other End Users
  (Note: Other end users include contract research organizations and agriculture companies.)

Artificial Intelligence in Genomics Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of APAC (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLA)
• Middle East & Africa

About Meticulous Research®

Meticulous Research® is a leading provider of comprehensive market intelligence, offering actionable insights and analysis across various industries. Our reports empower businesses to make informed decisions, drive growth, and remain competitive in a rapidly evolving marketplace.

Contact:

Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research